Immunomimetic Designer Cells Protect Mice from MRSA Infection

[1]  R. Weissleder,et al.  Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Hume,et al.  Lysostaphin treatment of methicillin-resistant staphylococcus aureus keratitis in the rabbit(1) , 2000, American journal of ophthalmology.

[3]  W. Schaffner,et al.  Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies. , 1967, The Yale journal of biology and medicine.

[4]  R. Landmann,et al.  Foreign Body Infection Models to Study Host-Pathogen Response and Antimicrobial Tolerance of Bacterial Biofilm , 2014, Antibiotics.

[5]  Luke S P Moore,et al.  Antimicrobials: access and sustainable eff ectiveness 2 Understanding the mechanisms and drivers of antimicrobial resistance , 2015 .

[6]  K. Doran,et al.  Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus , 2016, Scientific Reports.

[7]  C. Buchanan,et al.  Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation , 2007, Xenotransplantation.

[8]  S. Walsh,et al.  Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol , 2003, Antimicrobial Agents and Chemotherapy.

[9]  J. Kokai-Kun,et al.  Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[10]  Brad Spellberg,et al.  The future of antibiotics and resistance. , 2013, The New England journal of medicine.

[11]  S. Paik,et al.  Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide , 2007, Cell.

[12]  N. Lin,et al.  Highly potent antimicrobial modified peptides derived from the Acinetobacter baumannii phage endolysin LysAB2 , 2017, Scientific Reports.

[13]  Anthony S Fauci,et al.  The perpetual challenge of antimicrobial resistance. , 2014, JAMA.

[14]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[15]  Matthew A. Bochenek,et al.  Long term Glycemic Control Using Polymer Encapsulated, Human Stem-Cell Derived β-cells in Immune Competent mice , 2016, Nature Medicine.

[16]  Martin Fussenegger,et al.  SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus α-amylase , 2002 .

[17]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[18]  D. Philpott,et al.  Recognition of Staphylococcus aureus by the Innate Immune System , 2005, Clinical Microbiology Reviews.

[19]  B. Pulendran,et al.  Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. , 2014, Cell reports.

[20]  J. Rossi,et al.  Effect of Enrichment Procedure upon Auxotroph Recovery in Escherichia coli K-12 , 1975, Antimicrobial Agents and Chemotherapy.

[21]  J. Mond,et al.  Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. , 2009, The Journal of antimicrobial chemotherapy.

[22]  K. Plaut,et al.  Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice , 2001, Nature Biotechnology.

[23]  S. Paik,et al.  Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. , 2009, Immunity.

[24]  K. Schleifer,et al.  Description of a New Species of the Genus Staphylococcus: Staphylococcus carnosus , 1982 .

[25]  Clinical,et al.  Performance standards for antimicrobial susceptibility testing , 2019 .

[26]  L. Weisman,et al.  Treatment of Methicillin-Resistant Staphylococcus aureus in Neonatal Mice: Lysostaphin Versus Vancomycin , 2009, Pediatric Research.

[27]  R. Darouiche,et al.  Treatment of infections associated with surgical implants. , 2004, The New England journal of medicine.

[28]  D. Arifin,et al.  Synthesis of magnetic resonance–, X-ray– and ultrasound-visible alginate microcapsules for immunoisolation and noninvasive imaging of cellular therapeutics , 2011, Nature Protocols.

[29]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[30]  Clinical practice , 2011, European Journal of Pediatrics.

[31]  R. Marschalek,et al.  Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. , 2015, Biotechnology journal.

[32]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[33]  K. Jooss,et al.  An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  R. Landmann,et al.  Reversible Daptomycin Tolerance of Adherent Staphylococci in an Implant Infection Model , 2011, Antimicrobial Agents and Chemotherapy.

[35]  Martin Fussenegger,et al.  A synthetic multifunctional mammalian pH sensor and CO2 transgene-control device. , 2014, Molecular cell.

[36]  Edorta Santos,et al.  Cell encapsulation: technical and clinical advances. , 2015, Trends in pharmacological sciences.

[37]  I. Sutherland,et al.  The biofilm matrix--an immobilized but dynamic microbial environment. , 2001, Trends in microbiology.

[38]  A. J. Mixson,et al.  Alteration in the IL‐2 signal peptide affects secretion of proteins in vitro and in vivo , 2005, The journal of gene medicine.

[39]  M. Devocelle,et al.  Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives. , 2012, FEMS immunology and medical microbiology.

[40]  Lee H Harrison,et al.  National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. , 2013, JAMA internal medicine.

[41]  T. Hartung,et al.  Cellular trafficking of lipoteichoic acid and Toll‐like receptor 2 in relation to signaling; role of CD14 and CD36 , 2008, Journal of leukocyte biology.

[42]  J. Pedraz,et al.  Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[43]  R. Proctor.  Challenges for a universal Staphylococcus aureus vaccine. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  G. Archer,et al.  Combinations of Lysostaphin with β-Lactams Are Synergistic against Oxacillin-Resistant Staphylococcus epidermidis , 2002, Antimicrobial Agents and Chemotherapy.

[45]  M. Merad,et al.  Gut microbiota promote hematopoiesis to control bacterial infection. , 2014, Cell host & microbe.

[46]  C. E. McCormack,et al.  Do you know the sex of your cells? , 2014, American journal of physiology. Cell physiology.

[47]  Javariah Fatima,et al.  Treatment and outcomes of aortic endograft infection. , 2015, Journal of vascular surgery.

[48]  G. Archer,et al.  Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin , 1999, Antimicrobial Agents and Chemotherapy.

[49]  Vance G. Fowler,et al.  Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management , 2015, Clinical Microbiology Reviews.

[50]  P. Warn,et al.  MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin. , 2013, The Journal of antimicrobial chemotherapy.

[51]  J. Leppilahti,et al.  Two-stage revision for prosthetic joint infection: outcome and role of reimplantation microbiology in 107 cases. , 2014, The Journal of arthroplasty.

[52]  B. Penke,et al.  TLR2 Is a Primary Receptor for Alzheimer’s Amyloid β Peptide To Trigger Neuroinflammatory Activation , 2012, The Journal of Immunology.

[53]  S. Walsh,et al.  Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model , 2003, Antimicrobial Agents and Chemotherapy.

[54]  L. McCaig,et al.  Staphylococcus aureus–associated Skin and Soft Tissue Infections in Ambulatory Care , 2006, Emerging infectious diseases.

[55]  A. Fauci,et al.  Antimicrobial Resistance. , 2016, JAMA.

[56]  N. Davies,et al.  Hydrogen/deuterium exchange on aromatic rings during atmospheric pressure chemical ionization mass spectrometry. , 2010, Rapid communications in mass spectrometry : RCM.

[57]  Patricia Muñoz,et al.  Contemporary clinical profile and outcome of prosthetic valve endocarditis. , 2007, JAMA.

[58]  K. Becker,et al.  In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood , 2003, Antimicrobial Agents and Chemotherapy.

[59]  S. Ryser,et al.  A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model , 2016, Antimicrobial Agents and Chemotherapy.

[60]  Zhifeng Shao,et al.  Fc-fusion proteins: new developments and future perspectives , 2012, EMBO molecular medicine.

[61]  J. S. Goodman,et al.  Lysostaphin: an enzymatic approach to staphylococcal disease. 3. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. , 1968, The Yale journal of biology and medicine.

[62]  Tin-Yun Ho,et al.  Noninvasive nuclear factor-kappaB bioluminescence imaging for the assessment of host-biomaterial interaction in transgenic mice. , 2007, Biomaterials.

[63]  D. Vignali,et al.  Design and construction of 2A peptide-linked multicistronic vectors. , 2012, Cold Spring Harbor protocols.

[64]  Robert E. W. Hancock,et al.  Can innate immunity be enhanced to treat microbial infections? , 2004, Nature Reviews Microbiology.

[65]  E. Hume,et al.  Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. , 2000, Investigative ophthalmology & visual science.

[66]  J. Stelling,et al.  β-cell–mimetic designer cells provide closed-loop glycemic control , 2016, Science.

[67]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  Min Zhang,et al.  Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins* , 2002, The Journal of Biological Chemistry.

[69]  G. Corey,et al.  Methicillin-resistant Staphylococcus aureus: an evolving pathogen. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  M. Artenstein,et al.  Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient. , 1974, The New England journal of medicine.

[71]  M. Gossen,et al.  Improved Tet-responsive promoters with minimized background expression , 2010, BMC biotechnology.

[72]  C. Schindler,et al.  LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS. , 1964, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Pedraz,et al.  Inactivation of encapsulated cells and their therapeutic effects by means of TGL triple-fusion reporter/biosafety gene. , 2013, Biomaterials.

[74]  D. Webb,et al.  Oxidized Phospholipid Inhibition of Toll-like Receptor (TLR) Signaling Is Restricted to TLR2 and TLR4 , 2008, Journal of Biological Chemistry.

[75]  Timothy J. Foster,et al.  Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus , 2013, Nature Reviews Microbiology.

[76]  H. Boucher,et al.  Epidemiology of methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[77]  Thomas Bjarnsholt,et al.  The in vivo biofilm. , 2013, Trends in microbiology.

[78]  S. Elledge,et al.  Synthetic design of strong promoters , 2010, Proceedings of the National Academy of Sciences.

[79]  R. L. Harris,et al.  Effect of lysostaphin on staphylococcal carriage in infants and children. , 1967, Antimicrobial agents and chemotherapy.

[80]  I. Henderson,et al.  Alternatives to antibiotics-a pipeline portfolio review. , 2016, The Lancet. Infectious diseases.

[81]  Smaroula Dilioglou,et al.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector , 2004, Nature Biotechnology.

[82]  F. Götz,et al.  Influence of Lif, the Lysostaphin Immunity Factor, on Acceptors of Surface Proteins and Cell Wall Sorting Efficiency inStaphylococcus carnosus , 1998, Journal of bacteriology.

[83]  Stian Knappskog,et al.  The level of synthesis and secretion of Gaussia princeps luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide. , 2007, Journal of biotechnology.

[84]  Mingqi Xie,et al.  Self-adjusting synthetic gene circuit for correcting insulin resistance , 2016, Nature Biomedical Engineering.

[85]  P. Jakob,et al.  Bioluminescence and 19F Magnetic Resonance Imaging Visualize the Efficacy of Lysostaphin Alone and in Combination with Oxacillin against Staphylococcus aureus in Murine Thigh and Catheter-Associated Infection Models , 2013, Antimicrobial Agents and Chemotherapy.

[86]  A. Gurtman,et al.  Vaccine development to prevent Staphylococcus aureus surgical‐site infections , 2017, The British journal of surgery.

[87]  J. Greenleaf,et al.  Sonication of removed hip and knee prostheses for diagnosis of infection. , 2007, The New England journal of medicine.

[88]  W. Schaffner,et al.  Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. , 1967, The Yale journal of biology and medicine.

[89]  David L. Smith,et al.  Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999–2005 , 2007, Emerging infectious diseases.

[90]  Robin Patel,et al.  Clinical practice. Infection associated with prosthetic joints. , 2009, The New England journal of medicine.

[91]  D. Nicolau,et al.  Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model , 2010, Antimicrobial Agents and Chemotherapy.

[92]  H. Park,et al.  High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice , 2011, PloS one.

[93]  Michael A Mont,et al.  Periprosthetic joint infection , 2016, The Lancet.

[94]  K. Jooss,et al.  Stable antibody expression at therapeutic levels using the 2A peptide , 2005, Nature Biotechnology.

[95]  T. Jensen,et al.  Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells , 2002, Nature Biotechnology.

[96]  Anthony S Fauci,et al.  The perpetual challenge of infectious diseases. , 2012, The New England journal of medicine.

[97]  Robert Langer,et al.  Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates , 2016, Nature Biotechnology.

[98]  J. Mond,et al.  Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. , 2007, The Journal of antimicrobial chemotherapy.